Edwards' minimally-invasive valve surgery tech beats sternotomy – trial
This article was originally published in Clinica
Executive Summary
Edwards Lifesciences’ Port Access system, developed for use in mitral valve surgery, is safer than conventional sternotomy, a trial has suggested.
You may also be interested in...
Novartis Draws Out Its APPLAUSE
Another data drop from Fabhalta’s IgAN trial looks encouraging, despite a missing abstract.
Roche Steals A March In B-cell Lymphoma
New data on Columvi could allow the bispecific’s use as an earlier treatment, giving it a three-year head start on AbbVie and Genmab’s Epkinly.
PureTech Hopes For A Second Lightning Strike
Emerging Company Profile: Seaport Therapeutics believes its technology can alter old drugs to remove their flaws. Just how closely can it follow the example set by Karuna?